Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

Related Articles by Review for PubMed (Select 17239888)

1.

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).

McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, McGovern ME.

Atherosclerosis. 2007 Jun;192(2):432-7. Epub 2007 Jan 19.

PMID:
17239888
2.

Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).

Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ.

Am J Cardiol. 2010 Jan 1;105(1):69-76. doi: 10.1016/j.amjcard.2009.08.651. Review.

PMID:
20102893
3.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

4.

Managing dyslipidemia in the high-risk patient.

Stein EA.

Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. Review.

PMID:
11900720
5.
6.

Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.

Vo AN, Kashyap ML.

Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1303-10. doi: 10.1586/14779072.6.10.1303. Review.

PMID:
19018682
8.

Combination Therapy Versus Intensification of Statin Monotherapy: An Update [Internet].

Monroe AK, Gudzune KA, Sharma R, Chelladurai Y, Ranasinghe PD, Ansari MT, Robinson KA.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Feb.

9.

Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery.

Cooper DL, Murrell DE, Roane DS, Harirforoosh S.

Int J Pharm. 2015 Jul 25;490(1-2):55-64. doi: 10.1016/j.ijpharm.2015.05.024. Epub 2015 May 15. Review.

PMID:
25987211
10.

Ezetimibe Plus Moderate-dose Simvastatin After Acute Coronary Syndrome: What Are We IMPROVEing On?

DiNicolantonio JJ, Chatterjee S, Lavie CJ, Bangalore S, O'Keefe JH.

Am J Med. 2015 Feb 27. pii: S0002-9343(15)00166-7. doi: 10.1016/j.amjmed.2015.01.034. [Epub ahead of print] Review.

PMID:
25731133
11.

Drug Class Review: Fixed Dose Combination Drug Products for the Treatment of Type 2 Diabetes and Hyperlipidemia: Final Report [Internet].

McDonagh M, Peterson K, Thakurta SG, Dana T.

Portland (OR): Oregon Health & Science University; 2007 Oct.

12.

Comparative Effectiveness of Lipid-Modifying Agents [Internet].

Sharma M, Ansari MT, Soares-Weiser K, Abou-setta AM, Ooi TC, Sears M, Yazdi F, Tsertsvadze A, Moher D.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Sep.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk